By Fineline Cube 
Akeso Biopharma (HKG: 9926) announced it has received marketing approval from China’s National Medical Products Administration (NMPA) for gumokimab (AK111), an interleukin-17A (IL-17A) monoclonal antibody, for the treatment of moderate-to-severe plaque psoriasis in adult patients, marking the company’s entry into the competitive biologics market for autoimmune diseases.
Regulatory Milestone
| Item | Detail |
|---|---|
| Company | Akeso Biopharma (HKG: 9926) |
| Product | Gumokimab (AK111) |
| Drug Class | IL-17A monoclonal antibody |
| Regulatory Authority | National Medical Products Administration (NMPA), China |
| Approval Status | Marketing approval granted |
| Indication | Moderate-to-severe plaque psoriasis |
| Additional Indications | Active ankylosing spondylitis (under NMPA review) |
| Announcement Date | 11 Jun 2026 |
Drug Profile & Mechanism of Action
- Molecule: Gumokimab (AK111) – human monoclonal antibody targeting IL-17A
- Target: Interleukin-17A (IL-17A), a pro-inflammatory cytokine
- Source Cells: Primarily secreted by activated Th17 (T helper 17) cells
- Mechanism: Specifically binds to IL-17A, blocking its interaction with the IL-17 receptor (IL-17R) and inhibiting downstream immune-inflammatory signaling pathways
- Therapeutic Rationale: Disrupts the key inflammatory cascade driving psoriasis pathogenesis and joint inflammation in ankylosing spondylitis
IL-17A plays a central role in the immunopathology of multiple autoimmune conditions by mediating inflammatory responses upon binding to cell surface receptors. By neutralizing IL-17A activity, gumokimab addresses the core inflammatory driver rather than merely managing symptoms, offering potential for superior clinical outcomes compared to conventional therapies.
Market Impact & Commercial Strategy
- Psoriasis Market in China: Estimated 6-8 million patients with moderate-to-severe disease; biologics penetration currently below 15% but growing rapidly
- Competitive Landscape: Enters crowded IL-17 inhibitor space competing against Novartis’s Cosentyx (secukinumab), Eli Lilly’s Taltz (ixekizumab), and domestic biosimilars
- Pricing Advantage: Expected to be priced 20-30% below originator products, leveraging Akeso’s domestic manufacturing capabilities
- Revenue Projection: Peak annual sales estimated at RMB 1.5-2.0 billion (USD 205-275 million) across approved indications
- Pipeline Expansion: Ankylosing spondylitis approval expected within 6-12 months, potentially doubling addressable patient population
- Global Ambitions: Akeso plans international regulatory submissions following Chinese commercial launch, targeting Southeast Asian markets initially
The approval positions Akeso as a significant player in China’s rapidly expanding autoimmune biologics market and validates the company’s antibody development platform capabilities.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, market opportunities, and commercial projections. Actual results may differ due to competitive dynamics, pricing pressures, and regulatory developments.-Fineline Info & Tech